Sangamo Therapeutics, Inc.
SGMOSangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
Drugs in Pipeline
9
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and market intelligence
0 upcoming, 1 past
No catalysts found.
AI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Plerixafor
Sickle Cell Disease
CERE-120: Adeno-Associated Virus Delivery of Neurturin
Idiopathic Parkinson's Disease
CERE-110: Adeno-Associated Virus injection Surgery
Alzheimer's Disease
TX200-TR101
Kidney Transplant Rejection
ST-920
Fabry Disease
SB-728-T
HIV
Cyclophosphamide
Human Immunodeficiency Virus (HIV)
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Idiopathic Parkinson's Disease
SB-509
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Plerixafor | Phase 2 | Sickle Cell Disease | - |
CERE-120: Adeno-Associated Virus Delivery of Neurturin | Phase 2 | Idiopathic Parkinson's Disease | - |
CERE-110: Adeno-Associated Virus injection Surgery | Phase 2 | Alzheimer's Disease | - |
TX200-TR101 | Phase 2 | Kidney Transplant Rejection | - |
ST-920 | Phase 2 | Fabry Disease | - |
SB-728-T | Phase 2 | HIV | - |
Cyclophosphamide | Phase 2 | Human Immunodeficiency Virus (HIV) | - |
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | Phase 2 | Idiopathic Parkinson's Disease | - |
SB-509 | Phase 2 | Diabetes Mellitus, Type 1 | - |
Regulatory & News
Approvals, filings, and latest developments